Biogen beats revenue expectations, lifts investor confidence with 3% sales rise

Biogen reported $2.7 billion in revenue for the April‑June quarter, a 3% increase year over year, surpassing analysts' consensus estimate of $2.5 billion. Adjusted earnings per share came in at $3.60, beating the expected $2.88.

Key products helped drive the beat, with Spinraza sales climbing 7% to $402 million and royalty income of $381 million from Roche’s multiple sclerosis drug Ocrevus adding to the top line.

Analysts, including Jefferies, noted the stronger‑than‑expected results as a sign of portfolio resilience, and the market responded positively, restoring confidence in Biogen’s growth outlook. The report was released alongside earnings updates from AstraZeneca and GSK, which are also working to convince investors they can meet ambitious revenue targets.